posit read-through
coverag barclay research inform compani
provid inform purpos invest recommend
barclay research
cover report result today highlight key takeaway
releas call relat pend myl/upjohn merger see reason ow
post deal implic gener outlook improv
rais upjohn china outlook mid-to-high single-digit growth low-
to-mid single-digit management anticip improv upon previous issu
sale guidanc upjohn cite mitig impact vbp
program china expans provinc vbp implement
growth opportun emerg market ex-china posit read-
partial address one key question get merger
follow upon posit biosimilar read-through partner biocon last week
biosimilar read-through biocon result remain ow
overal upjohn perform upjohn revenu total quarter
y/i oper driven lyrica loe exclud lyrica
headwind revenu declin oper basi effexor zoloft
grew y/i revenu primarili come intern market
oper driven volum growth lipitor/norvasc provinc
volume-bas procur vbp program isnt yet implement oper
growth viagra partial off-set volum declin unfavor
price impact lipitor/norvasc citi vbp program implement
march addit outlook upjohn improv expect
upjohn china revenu grow mid-to-high singl digit oper
quarterli annual ep usd
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight ow base
extens biosimilar portfolio partnership
biocon think give edg truli
diversifi global segment complex gener
strong uptak wixela yupelri gcopaxon
delay grestasi disappoint commerci
valuat valu stand-alon basi ntm ev/ebitda
risk delay grestasi disappoint commerci progress worsen gx
environ potenti legal hurdl upjohn deal fall
balaji prasad md herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
procedur pleas
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
unless otherwis indic price sourc bloomberg reflect close price relev trade market may
last avail price time public
